Back to News
Market Impact: 0.15
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead
Source: etftrends.com
Healthcare & BiotechMarket Technicals & Flows
Amplify Weight Loss Drug & Treatment ETF (THNR) refreshed its holdings following a scheduled Sept. rebalancing of its underlying VettaFi Weight Loss Drug & Treatment Index (THINR). The update reflects ongoing changes in the competitive landscape for weight-loss drug developers and treatment providers, but the article provides no specific constituent changes, weights, or performance figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- AMD joins the $1 trillion club as chip rally surges - our AI Strategy saw it early
- +17% in a single session: This AI-picked stock catches a data-center breakout
- India Proprietary Trading Slumps on Auction Liquidity Woes, Trading Curbs
- Asia stocks rise tracking U.S. tech rally; Trump-Xi meeting eyed
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Chip stocks snap back on multi-billion-dollar AI bet - AI Strategy got in early